Class / Patent application number | Description | Number of patent applications / Date published |
514700500 | Protein tyrosine kinase (PTK) affecting | 10 |
20100298217 | CSF-1R MUTANTS - Provided are mutant class III receptor tyrosine kinases (RTKIII) comprising a mutation at the amino acid residue corresponding to the conserved cysteine at residue 432 (C432) or 439 (C439) of a mouse colony-stimulating factor (1) receptor (CSF-IR) precursor having the amino acid sequence of SEQ ID NO: 1, where the mutation is a replacement of the cysteine with an amino acid having an uncharged polar R group. Also provided are mutant RTKIIIs comprising a tyrosine to phenylalanine mutation. Additionally provided are extracellular domains of the above-identified mutant RTKIIIs comprising cysteine to serine mutations. Further provided are stable cell lines of macrophages lacking a native CSF-IR. Also provided are isolated nucleic acids encoding any of the above-described mutant RTKIIIs or extracellular domains. Vectors comprising those nucleic acids are also provided. Additionally provided are methods of preparing the above-identified stable cell lines. Methods of treating a mammal comprising administering the above described extracellular domain to the mammal are also provided. | 11-25-2010 |
20100323957 | NOVEL ASSAY FOR INHIBITORS OF EGFR - The invention provides methods and compositions for screening for modulators of EGFR activity. In particular, an assay for such modulators is provided, which includes methods of screening for modulators using models of the three dimensional structure of EGFR kinase domains. | 12-23-2010 |
20110021424 | POLYPEPTIDE DERIVED FROM PROTEIN A AND ABLE TO BIND PDGF - The invention provides a platelet derived growth factor receptor beta (PDGF-Rβ) binding polypeptide, comprising a platelet derived growth factor receptor beta binding motif, PBM, which motif consists of an amino acid sequence as defined herein, wherein the PDGF-Rβ-binding polypeptide binds to PDGF-Rβ such that the K | 01-27-2011 |
20110245167 | NaK-ATPase-Derived Peptide SRC Inhibitors and Ouabain Antagonists and Uses Thereof - A novel Src inhibitor that targets the Na/K-ATPase/Src receptor complex and antagonizes ouabain-induced protein kinase cascades and uses thereof are disclosed. | 10-06-2011 |
20120289463 | Compositions and Methods for Promoting Epithelialization and Wound Closure - Compositions for antagonizing phosphorylation and subsequent degradation of glycogen synthase kinase 3 beta (GSK3β) in epidermal cells are disclosed. GSK3β phosphorylation antagonists include molecules that function to inhibit or reduce the binding activity or enzymatic activity of an upstream signaling molecule leading to GSK3β phosphorylation, or by downregulating the expression of one or more upstream signaling molecules involved in regulating GSK3β phosphorylation. Methods of using the GSK3β phosphorylation antagonists to inhibit or reduce the phosphorylation and degradation of GSK3β in epidermal cells are provided. The methods are useful to promote epithelialization and closure of wounds, such as chronic non-healing wounds. | 11-15-2012 |
20130150294 | Na+/K+-ATPase-Specific Peptide Inhibitors/Activators of Src and Src Family Kinases - A method for regulating Src and its downstream signaling pathway which includes binding between Src and Na+/K+-ATPase is disclosed. The Na+/K+-ATPase/Src complex is a functional receptor for cardiotonic steroids such as ouabain. Also disclosed are Src inhibitors or activators which include either Na+/K+-ATPase or Src that interfere with the interaction between the Na/K-ATPase and Src, act via a different mechanism from ATP analogues, and is pathway (Na+/K+-ATPase) specific. | 06-13-2013 |
20140187484 | NA/K-ATPASE-DERIVED PEPTIDE SRC INHIBITORS AND OUABAIN ANTAGONISTS AND USES THEREOF - A novel Src inhibitor that targets the Na/K-ATPase/Src receptor complex and antagonizes ouabain-induced protein kinase cascades and uses thereof are disclosed. | 07-03-2014 |
20140315801 | METHODS OF TREATMENT OF CELL PROLIFERATIVE AND/OR OPHTHALMIC DISEASES, DISORDERS AND CONDITIONS USING INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY - This invention relates to methods for treating cell proliferative diseases and conditions and ophthalmic diseases, disorders and conditions using compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to the methods of treatment which utilize compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling. | 10-23-2014 |
20160058828 | METHODS, USES AND COMPOSITIONS OF TIE2 AGONISTS - The present disclosure provides methods and uses of Tie2 agonists alone or in combination with antiviral agents. In particular, the present disclosure provides methods and uses for treating influenza, treating a bacterial superinfection associated with influenza and decreasing lung endothelial leakage. The disclosure also provides compositions comprising (a) a Tie2 agonist and (b) an antiviral agent and methods and uses thereof. | 03-03-2016 |
20160200780 | MUTEINS WITH TEAR LIPOCALIN HAVING AFFINITY TO HUMAN C-MET RECEPTOR TYROSINE KINASE AND METHODS FOR OBTAINING THE SAME | 07-14-2016 |